PROCEPT BioRobotics Corp
Close on Oct 19, 2026
- Market cap
- $1.04B
- P/E (TTM)
- –
- Dividend yield
- –
About PROCEPT BioRobotics
Surgical & Medical Instruments & Apparatus, SIC 3841
The company develops, manufactures, and sells image-guided surgical robotic systems for minimally invasive urology, focusing on treating benign prostatic hyperplasia. Its primary products are the AquaBeam Robotic System and the HYDROS Robotic System. Each system utilizes single-use disposable handpieces to deliver Aquablation therapy, combining ultrasound imaging, robotic automation, and heat-free waterjet ablation to remove prostate tissue. The company primarily sells its products to hospitals, as well as to ambulatory surgery centers, distribution partners, and leasing companies.
The company maintains an installed base of 912 robotic systems globally, including 718 units in the United States and the remainder internationally. It sells through a direct sales organization in the United States targeting urologists across approximately 2,700 hospitals. Internationally, sales occur through direct personnel and third-party distribution partners. The provided text does not mention the company's headquarters location.
Summary of the business section of PROCEPT BioRobotics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PROCEPT BioRobotics Corp
- Headquarters
- San Jose, CA
- Address
- 150 Baytech Drive 95134
- Phone
- (650) 232-9832
- Employees
- 888, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- PRCT
- Exchange
- Nasdaq
- IPO date
- Sep 16, 2021
- Shares outstanding
- 57M, Jul 31, 2026
- Public float
- $3.20B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1588978
- CUSIP
- 74276L105
- ISIN
- US74276L1052
- EIN
- 26-0199180
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Larry L. Wood | President, CEO, Director | 338,103 |
| Reza Zadno | President, CEO, Director | 186,829 |
| Barry L. Templin | EVP, Chief Technology Officer | 151,283 |
| Kevin Waters | EVP, CFO | 180,355 |
| Alaleh Nouri | EVP, CLO, CORP. SEC. | 127,737 |
| Pooja Sharma | Chief Strat/Marketing Officer | 111,181 |
| Hisham Shiblaq | EVP, Chief Comm. Officer | 83,133 |
| Amy M. Dodrill | Director | 10,941 |
| Dan Puckett | Director | 8,791 |
| Taylor C. Harris | Director | 137,565 |
| Thomas M. Prescott | Director | 7,211 |
| Mary Garrett | Director | 17,700 |
| Elisabeth Sandoval Little | Director | 15,876 |
| Antal Rohit Desai | Director | 477,792 |
| Frederic H. Moll | Director | 866,474 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Larry L.Wood | $16.78M | $13.07M | $2.33M | $75 | $105 |
| FY2025 Reza Zadno Ph.D | $6.77M | -$7.59M | $2.33M | $75 | $105 |
| FY2024 Larry L.Wood | $0 | $0 | $2.81M | $192 | $97 |
| FY2024 Reza Zadno Ph.D | $6.52M | $17.83M | $2.81M | $192 | $97 |
| FY2024 Reza Zadno, Ph.D | $6.52M | $17.83M | $2.81M | $192 | $97 |
| FY2023 Larry L.Wood | $0 | $0 | $2.49M | $100 | $87 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 888 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 16, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 10, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |